ReadyCure is developing the world's first medical device to treat Alzheimer's disease dementia.
Based on the results of early exploratory clinical studies on the therapeutic effects of low-dose radiation, Helaxon, a dedicated radiation therapy system for dementia, is currently being developed.
The use of high-power carbon nanotubes in radiation therapy can be expected to be economical and superior to conventional X-ray generators of filamentous methods.
In addition, there is a big difference in that it can save 60-70% of drug treatment costs without side effects and provides fundamental treatment rather than slowing the progress of the disease.
ReadyCure's initiative aims to reduce national health care costs, promote socioeconomic benefits, and improve the quality of life for patients and their caregivers with fundamental treatment of Alzheimer's dementia, an irreversible degenerative change.